Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPX-501 T Cells in Pediatric HSCT
NCT02065869Phase 2Terminated
- Sponsor
- Bellicum Pharmaceuticals, Inc.
- Start
- Apr 2014
- Primary completion
- Jun 2020
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
A Phase 2 trial of rivogenlecleucel in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), primary immunodeficiency (PI), aplastic anemia, sponsored by Bellicum Pharmaceuticals, Inc.. Started Apr 2014; status: terminated.
02
Drugs
rivogenlecleucel
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)primary immunodeficiency (PI)aplastic anemia
Beyond the preview
Go deeper on NCT02065869.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02065869.